Pyridostigmine Treatment for Pediatric Axonal Guillain-Barré Syndrome.

Key Points

• Investigate the safety and effectiveness of pyridostigmine as a treatment for pediatric axonal Guillain-Barré Syndrome (GBS).
• Evaluated pyridostigmine as an add-on treatment for pediatric patients with axonal GBS.
• Assessed patient response to immune therapy prior to pyridostigmine treatment.
• Considered effectiveness during late stages of GBS.
• Pyridostigmine was found to be safe for use in pediatric patients.
• Significant improvement noted in patients with insufficient response to immune therapy.
• Encouraging results suggest the potential for later-stage treatment application.